1 / 32

Emerging Data on ACS Management From ACC

Emerging Data on ACS Management From ACC. Assessing the Impact of Medication Affordability on Prescribing Patterns and Patient Adherence. Background. Hypotheses. ARTEMIS: Study Design. ARTEMIS: Clinicians Are Sensitive to Patient Costs. ARTEMIS Non-Persistence of P2Y 12 Inhibitor.

ainsley-leblanc
Télécharger la présentation

Emerging Data on ACS Management From ACC

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Emerging Data on ACS Management From ACC

  2. Assessing the Impact of Medication Affordability on Prescribing Patterns and Patient Adherence

  3. Background

  4. Hypotheses

  5. ARTEMIS: Study Design

  6. ARTEMIS: Clinicians Are Sensitive to Patient Costs

  7. ARTEMISNon-Persistence of P2Y12 Inhibitor

  8. ARTEMISMACE and As-Treated Analysis

  9. Conclusions/Clinical Pearls

  10. Exploring the Safety of P2Y12 Inhibitors in STEMI Patients Receiving Fibrinolytic Therapy

  11. TREAT Study Fills PLATO Study Gap

  12. TREAT Trial: Design and Methods

  13. TREAT Trial: Results

  14. TREAT Study: Principal Findings (30 Days)

  15. Conclusions/Clinical Pearls

  16. The Correlation Between Prescription Supply and Medication Adherence After Acute Myocardial Infarction

  17. 30- vs 90-Day Prescription Supply Study: Background and Methods

  18. 30- vs 90-Day Prescription Supply Study: Results

  19. 30- vs 90-Day Prescription Supply Study: Results (Baseline Characteristics)

  20. 30- vs 90-Day Prescription Supply Study Results (Adherence and Product Changes)

  21. Study Limitations

  22. Conclusions/Clinical Pearls

  23. The Clinical Implications of De-Escalating Antiplatelet Therapy

  24. DAPT Guideline Recommendations

  25. The Concept of De-Escalation

  26. Prevalence and Timing of De-Escalation Therapy in Patients With ACS

  27. Clinical Outcomes Associated With De-Escalation Therapy

  28. SWAP-4 Study Design

  29. SWAP-4 Study: Results and Conclusions

  30. Conclusions/Clinical Pearls

  31. Abbreviations

  32. Abbreviations (cont)

More Related